DCOY — Decoy Therapeutics Share News
0.000.00%
Last trade - 00:00Salarius Pharma up after FDA lifts hold on cancer study
Brief: FDA Removes Partial Clinical Hold On Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial With Seclidemstat In Patients With Ewing Sarcoma
Salarius Pharmaceuticals Inc expected to post a loss of $2.59 a share - Earnings Preview
Brief: Salarius Pharmaceuticals Reports No Adverse Safety Signals From Two Good Laboratory Practice Toxicology Studies With Its Targeted Protein Degrader Sp-3164
Brief: Salarius Pharmaceuticals Reports Q4 And Full Year 2022 Financial Results
Salarius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Salarius Pharmaceuticals Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Salarius Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview
Brief: Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At The Inaugural Molecular Glue Drug Development Summit
U.S. STOCKS ON THE MOVE-Lamb Weston Foldings, Stitch Fix, Bellerophon Therapeutics
U.S. STOCKS ON THE MOVE-Boxed Inc, Oil companies, Tesla
Salarius Pharma rises on U.S. patent for potential cancer therapy
Brief: Salarius Pharmaceuticals Issues New U.S. Patent For Next Gen Targeted Protein Degraders
Brief: Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity In Preclinical Lymphoma Models At The American Society Of Hematology Annual Meeting
Brief: Salarius Pharmaceuticals Announces Interim Results From Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing Sarcoma And Fet-Rearranged Sarcomas
Salarius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Salarius Pharmaceuticals Reports Third Quarter Results
Salarius Pharmaceuticals Inc expected to post a loss of $2.55 a share - Earnings Preview
Brief: Salarius Pharmaceuticals Presents Favorable Preclinical Data On SP-3164